Floatz logo

15 assets in Oropharyngeal Carcinoma

Therapeutic assets addressing Oropharyngeal Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Oropharyngeal Carcinoma
HRYZ Biotech Co.P2BB (70)
Fludarabine
Oropharyngeal Carcinoma
HRYZ Biotech Co.P2BB (68)
Cis-Diamminedichloroplatinum Ii
Oropharyngeal Carcinoma
Loren Mell, MDP2B (60)
Pembrolizumab
Oropharyngeal Carcinoma
Inhibrx Biosciences, IncP2B (60)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P2B (57)
Ipilimumab
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dexasone
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Diphenhydramine
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Entinostat
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Epinephrine
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Ibuprofen
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
pds01adc
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Prgn-2009
Oropharyngeal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Hryz-T101 Tcr-T Cell
Oropharyngeal Carcinoma
HRYZ Biotech Co.P1CC (43)